Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Eplereone
- Registration Number
- NCT06556732
- Lead Sponsor
- Assiut University
- Brief Summary
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
- Detailed Description
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital, on 100 patients with AF and structural heart disease. AF is confirmed by electrocardiography. The patients were divided into 2 groups:
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Group B (control group): 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously
- Patients with rheumatic heart disease.
- Thyroid dysfunction.
- Wolf-Parkinson-White (WPW) syndrome.
- Renal impairment.
- Hyperkalemia.
- Acute coronary syndrome.
- Pregnancy.
- Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
- On current use of eplerenone.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Study arm Eplereone Were given Eplereone 25 mg daily Control arm Eplereone Were given nothing
- Primary Outcome Measures
Name Time Method AF recurrence 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assiut University Heart Hospital
🇪🇬Assiut, Egypt